# Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan

> **NCT02939287** · PHASE3 · COMPLETED · sponsor: **Rush University Medical Center** · enrollment: 52 (actual)

## Conditions studied

- Nausea
- Vomiting

## Interventions

- **DRUG:** o Aprepitant 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally on Days 0 and +1
- **DRUG:** Olanzapine10 mg orally daily on Days -1,0,+1 and +2
- **DRUG:** Aprepitant plus Olanzapine

## Key facts

- **NCT ID:** NCT02939287
- **Lead sponsor:** Rush University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-23
- **Primary completion:** 2021-12-30
- **Final completion:** 2022-12-01
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2024-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02939287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02939287, "Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02939287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*